Online patient communities have become a vital resource for rare disease patients, and pharma is coming round to the idea of engaging with them for real-world data.
As coronavirus vaccines and treatments advance rapidly through research and development, the world starts to consider what drugs and digital tools might be needed in the ‘new normal’.
Professor Paul Kaye from the University of York, whose research team was recently granted €8 million to help reduce the burden of leishmaniasis in African countries, takes us through the lo
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
